Abstract: The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.

Abstract: The invention is directed to a lactose-positive, galactose-negative, Streptococcus thermophilus strain releasing glucose during milk fermentation. This Streptococcus thermophilus strain carries mutation in the glcK gene, in the ccpA gene, in the lacZ gene and/or in the ptsH gene, and optionally in one or more genes, in particular one gene, encoding a protein of the mannose-glucose-specific PTS. The invention also concerns a composition comprising at least one, lactose-positive, galactose-negative, Streptococcus thermophilus strain of the invention, and the use of this strain or composition to manufacture a fermented dairy product.

Abstract: Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.

Abstract: The present disclosure discloses a Streptomyces antioxidans strain Sa-21, namely, strain Sa-21 with an accession number of CCTCC NO: M 2020423. The present disclosure also discloses the use of the aforementioned Strepiomyces antioxidans strain Sa-21 in inhibition of Alternaria solani (A. solani). The Streptomyces antioxidans strain also has an inhibiting effect on both plant pathogenic fungi and plant pathogenic bacteria.

Abstract: Neonatal seizure is different from adult seizure, and many anti epileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, and the glucose oxidase enzyme, is shown herein to potently inhibit neonatal epilepsy both in vitro and in vivo. Sodium gluconate is shown to inhibit epileptiform burst activity in cell cultures and protect neurons from kainic acid-induced cell death. Sodium gluconate also inhibited epileptiform burst activity in brain slices in a manner that was much more potent in neonatal animals than in older animals. Consistently, in vivo EEC recordings also revealed that sodium gluconate inhibited the epileptic seizure activity in a manner that was much more potent in neonates than in adult animals. Mechanistically, sodium gluconate inhibits voltage-dependent CLC-3 C1? channels both in neuronal cultures and in hippocampal slices.

Abstract: The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes.

Abstract: A method for cultivating micro-algae cultures using bivalve waste comprising usable nitrogen and phosphorus as a nutrient source. The micro-algae cultures may be used in turn as a nutrient source for oysters.

Abstract: The present invention relates to a process for the production of a dyed biopolymer comprising the steps of providing at least one biopolymer-producing microorganism, providing at least one dye-producing microorganism, culturing said at least one biopolymer-producing microorganism to produce at least a biopolymer, and culturing said dye-producing microorganism wherein said dye-producing microorganism produce at least a dye suitable to dye at least part of said biopolymer, whereby a dyed biopolymer is obtained. The present invention also relates to a dyed biopolymer, to process for the production of a dyed composite article comprising at least the dyed biopolymer and to articles comprising the dyed biopolymer.

Abstract: The present invention relates to a method and a drug for preventing or treating osteoarthritis by plasminogen. Specifically, the present invention involves administering an effective amount of plasminogen to an osteoarthritis subject for treating the osteoarthritis. In addition, the present invention further relates to an osteoarthritis treatment drug comprising plasminogen, a product, and a kit.

Abstract: A method of preparing a polyvinyl alcohol nanofiber membrane includes a material for controlling cell specific adhesion, and a nanofiber membrane that can maintain cellular functions such as cell activity and growth is prepared by adding aqueous solutions containing a polyacrylic acid and a glutaraldehyde crosslinking agent in a polyvinyl alcohol and materials capable of enhancing or regulating cell adhesion, electrospinning, treating with hydrochloric acid vapor and dimethylformaldehyde solvent and treating with sodium hydroxide to control the cell adhesion.

Abstract: The present invention relates to the field of fermentation biotechnology, more particularly to methods for the fermentative production of massoia lactone by Aureobasidium species.

Abstract: A method for producing a fermentate including the steps of obtaining a fruit or vegetable extract, treating the extract with a hydrolytic enzyme, mixing the extract with a fermenting microorganism, water, and a growth media to produce a liquid composition; and incubating the liquid composition at a controlled temperature and a controlled pH to produce a fermentate. A method for killing or inhibiting the growth of a contaminating microorganism on or within a food product, and a food product including a fermentate having a cellular mass component from a fermenting microorganism, a fermented fruit or vegetable extract and a hydrolytic enzyme are disclosed. A fermentate produced by any one of the methods described is contemplated. The fermentate may be a concentrated liquid or a dry powder and has the ability to inhibit the growth of a contaminating microorganism by 100% when diluted to less than 5% (w/v).

Abstract: Disclosed herein are therapeutic compositions and nutritional supplements comprising probiotic mixtures and sleep-support ingredients, and a method of treating digestive discomfort and sleep problems comprising administering an effective amount of a therapeutic composition comprising a probiotic component and a sleep support component. According to embodiments, therapeutic compositions for improved digestion are provided comprising: a probiotic component, comprising: at least one of Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium animalis, Lactobacillus rhamnosus, and Lactobacilus paracasei; and a sleep support component, comprising: at least one of gamma-aminobutyric acid (GABA), valerian root extract, and melatonin. The therapeutic compositions are effective in treating both sleep disorders and digestive discomfort.

Abstract: The present invention relates to the preventive or curative treatment of metabolic syndrome and the associated disorders with AhR agonist or microorganism producing AhR agonist.

Abstract: A sanitizing composition for restoring skin's natural balance of bacteria and/or increasing the production and/or activity of antimicrobial peptides is provided. The sanitizing composition includes about 0.005 wt. % to 15.0 wt. % of an active ingredient that is one or more of a probiotic, probiotic derivative, prebiotic, and a prebiotic derivative and at least one compound that delivers a sanitizing effect.

Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

Abstract: A composition containing enzymes, L-arginine, and other components for treating exocrine pancreatic enzyme insufficiencies and gastrointestinal disorders in mammals. The compositions replace pancreatic enzymes while concurrently treating the side effects of small intestinal bacterial overgrowth and gastrointestinal mucosal degeneration that occurs with pancreatic enzyme loss. The composition can be mixed into animal feeds or sprayed onto extruded feeds prior to consumption.

Abstract: A microbial inoculant composition includes aquatic bacterial species. In some embodiments, the microbial inoculant composition includes at least one of an aquatic Pseudomonas spp. and a Clostridium spp.

Abstract: Disclosed are date palm compositions and methods of use of such compositions. Such compositions may be used as part of a growth medium for culture of microorganisms. In certain embodiments, date palm extracts of the disclosure are used as part a culture medium to grow Lactobacilli.

Abstract: The disclosure is a composition for treating, preventing, ameliorating, or suppressing cancer, or inhibiting cancer metastasis, comprising a plant fermentation extract as an active ingredient, wherein the plant fermentation extract comprises a yeast that is viable in an environment at pH 1 and that is capable of forming spores in a complete medium.